3,798 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Acquired by Allstate Corp

Allstate Corp purchased a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 3,798 shares of the biopharmaceutical company's stock, valued at approximately $894,000.

A number of other institutional investors have also recently added to or reduced their stakes in ALNY. Larson Financial Group LLC lifted its stake in shares of Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 73 shares in the last quarter. R Squared Ltd purchased a new position in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $33,000. OFI Invest Asset Management acquired a new position in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $35,000. True Wealth Design LLC grew its stake in Alnylam Pharmaceuticals by 15,300.0% during the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company's stock worth $42,000 after buying an additional 153 shares during the period. Finally, Versant Capital Management Inc increased its position in shares of Alnylam Pharmaceuticals by 77.6% in the fourth quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 83 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company's stock.

Wall Street Analyst Weigh In

ALNY has been the topic of several recent research reports. Stifel Nicolaus lifted their target price on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a report on Monday, March 31st. Royal Bank of Canada boosted their price objective on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an "outperform" rating in a research note on Friday, March 21st. JPMorgan Chase & Co. upgraded Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and increased their target price for the company from $280.00 to $328.00 in a research note on Monday, March 24th. Citigroup raised their target price on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a "buy" rating in a report on Friday, March 21st. Finally, StockNews.com cut Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have issued a buy rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $316.25.

Remove Ads

Alnylam Pharmaceuticals Stock Performance

ALNY traded down $26.42 during trading hours on Friday, hitting $235.74. 1,881,579 shares of the stock were exchanged, compared to its average volume of 844,661. The stock has a market cap of $30.67 billion, a price-to-earnings ratio of -108.64 and a beta of 0.30. The stock has a 50-day simple moving average of $259.03 and a 200-day simple moving average of $260.23. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). Analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total transaction of $362,246.40. Following the completion of the transaction, the executive vice president now owns 12,881 shares in the company, valued at approximately $3,240,344.36. This represents a 10.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO Pushkal Garg sold 52,592 shares of the stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the sale, the chief marketing officer now directly owns 11,989 shares in the company, valued at approximately $3,416,865. This trade represents a 81.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 71,234 shares of company stock worth $19,958,097 over the last ninety days. Company insiders own 1.50% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.